Jun 10, 2026 07:13AM
Jun 9, 2026 07:45AM
Jun 9, 2026 07:45AM
Jun 1, 2026 07:01AM
Jun 1, 2026 07:00AM
May 11, 2026 07:03AM
May 11, 2026 07:00AM Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program
May 6, 2026 08:45AM
May 6, 2026 08:45AM
Apr 14, 2026 08:45AM
Apr 14, 2026 08:45AM
Mar 24, 2026 07:01AM
Mar 24, 2026 07:00AM
Mar 9, 2026 08:45AM Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors
Mar 4, 2026 05:00PM
Feb 24, 2026 08:45AM
Jan 21, 2026 08:45AM
Jan 21, 2026 08:45AM
Jan 12, 2026 08:45AM
Jan 12, 2026 08:45AM
Jan 6, 2026 02:26PM Lucid Capital Markets Reiterates Buy Rating on Actuate Therapeutics (ACTU)
Jan 6, 2026 08:45AM
Jan 6, 2026 08:45AM
Dec 18, 2025 08:45AM
Dec 18, 2025 08:45AM
Dec 15, 2025 08:45AM
Dec 15, 2025 08:45AM
Sep 23, 2025 06:37AM H.C. Wainwright Reiterates Buy Rating on Actuate Therapeutics (ACTU)
Sep 22, 2025 08:45AM
Sep 22, 2025 08:45AM
Aug 26, 2025 01:08AM
Aug 6, 2025 08:45AM
Aug 6, 2025 08:45AM
Jul 21, 2025 06:46AM
Jul 17, 2025 08:45AM Actuate Therapeutics reports positive phase 1 results for cancer drug
Jul 17, 2025 08:45AM
Jun 24, 2025 09:15AM
Jun 20, 2025 08:45AM
Jun 20, 2025 08:45AM
Jun 16, 2025 08:30AM
Jun 2, 2025 09:00AM
May 31, 2025 04:30PM Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment o
May 22, 2025 05:29PM
May 22, 2025 05:05PM
May 7, 2025 08:00AM
May 6, 2025 08:01AM
May 6, 2025 08:00AM
Apr 30, 2025 08:00AM
Apr 23, 2025 10:24AM Actuate to Present Elraglusib Phase 2 Topline Data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
Apr 17, 2025 08:00AM

322,999 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All